Tessera Therapeutics
Cell & Gene Therapy · Rare Disease Therapeutics
3open roles
$230Mlatest round · Venture round · May 2021 · 5 yr ago
3backers · Flagship Pioneering, Foresite Capital
317team · US Form 5500 (plan participants) · Dec 2025 · +3% in a year
Overview
Tessera Therapeutics is a biotechnology company pioneering Gene Writing technology to develop genetic medicines. It is developing in vivo CAR-T therapies that use targeted lipid nanoparticles to deliver CAR mRNA directly to T cells. The company is headquartered in Somerville, Massachusetts, United States.
Funding and backers
Total raised
$230M
1 round on record
Latest round
$230M
Venture round · May 2021 · 5 yr ago
Team
317
US Form 5500 (plan participants) · Dec 2025 · +3% in a year
Hiring now
4
+1 posted in 30 days
Backers
3
Flagship Pioneering, Foresite Capital
The money's age
Long since its last round
65 months since the last round · and hiring
Momentum
10/100
hiring for its size
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 23
New executive Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer - Company Announcement · markets.ft.com
Jan 12
Certified Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD · YahooFinance
Jun 15, 2021
Board appointment Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of Directors · Nasdaq
May 20, 2021
Raised a round Venture round $230M
Jul 2020
Website went live first capture in the Wayback Machine
Tractionpublic signals, read monthly
Web presence
top 5%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2021 | $230M | — | fiercebiotech.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Flagship Pioneering 
Foresite Capital 
Toba Capital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Mirai Bio is a privately held biotechnology company founded by Flagship Pioneering that develops delivery technologies for genetic…
High science that delivers.. Developing in vivo gene editing therapeutics to transform patient lives.
AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet…
Myosana Therapeutics is one of the pioneering companies in non-viral gene therapy for neuromuscular and cardiac diseases.
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
About Us We build the medicines we wish existed CPTx is a genetic medicines company redefining how we treat disease using immune-silent…
Jobs
$120k – $140k per year · In office · Contractor · 4+ years exp · PhD · Somerville
GMP
Apply
$164k – $199k per year · Equity · In office · 8+ years exp · Bachelor's Degree · Somerville
GCP
Apply
$141k – $171k per year · Equity · Hybrid · 12+ years exp · Bachelor's Degree · Somerville
Dagster
DevOps
AWS
Life Sciences
Next-Generation Sequencing
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$185k
Typical range
$140k – $335k
Open positions
4
4
Jobs
Middle
25%
Senior
50%
Architect
25%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Middle | 1 | $140k | $140k |
| Senior | 2 | $253k | $171k – $335k |
| Architect | 1 | $199k | $199k |
Highest paying role
Medical Monitor/Senior Medical Monitor, Hematology
$335k
Normalized to USD per year
Visa sponsorship
6 ▼ 75%
H-1B filings in 12 months
3
Green card filings
$116k
Median offered salary
Who they sponsor
Biochemists and biophysicists
3
Chemists
1
Other biological scientists
1
In the register as Tessera Therapeutics, Somerville, MA (+1 more)
Other sponsors in the same field
Vertex Pharmaceuticals 174 filings
Alnylam 36 filings
Sarepta 11 filings
Intellia Therapeutics 8 filings
See 4 open roles Alert me
US Department of Labor · latest filing Apr 16, 2026 · Visa details by country
Growth
Hiring Momentum
46/100
Stable
Open positions
4
1 opened / 2 closed in 30 days
Median time-to-fill
60 days
faster than 22% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
50%
Industrial Engineering
25% ▲
Biotech
25% ▼
Activity Timeline
Added GMP to stack
Oct 2026
Added HPLC to stack
Oct 2026
Added Next-Generation Sequencing to stack
Oct 2026
Financials
Total raised
$230M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2021 | $230M | Details |
Tech stack
Technologies named in job postings at Tessera Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
7
Postings analysed
6
Stack modernity
70/100
Frameworks & libraries
Dagster
Cloud & platforms
AWS
GCP
Practices & domains
GMP
Next-Generation Sequencing
AI Agents
HPLC
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD
SOMERVILLE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Tra
Read more
Report
Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD
SOMERVILLE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Inve
Read more
Report
Tessera Therapeutics Announces Chief Financial Officer (CFO) Transition and Appointment of Kathy Bergsteinsson as CFO
Read more
Report
Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of Directors
Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company' s Board of Directors. This announcement represents the latest key development for Tesse
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Somerville
Somerville
United States
HQ
Somerville, MA
4 open roles 4 posted in 90 days 50-200 est. staff $211k Avg Salary
hires for Biotech, Industrial Engineering, Early Careers